B
Bandaru S. Reddy
Researcher at Rutgers University
Publications - 277
Citations - 28225
Bandaru S. Reddy is an academic researcher from Rutgers University. The author has contributed to research in topics: Azoxymethane & Colorectal cancer. The author has an hindex of 97, co-authored 277 publications receiving 27634 citations. Previous affiliations of Bandaru S. Reddy include Pharmacia & Dana Corporation.
Papers
More filters
Journal ArticleDOI
Chemoprophylaxis of colon cancer.
TL;DR: Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal anti-inflammatory drugs, particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents, however, several of these chemopreventive agents induce side effects at effective high dose levels.
Journal Article
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
TL;DR: AOM-induced ODC and TPK activities were significantly suppressed by dietary DFMO progressively at all stages of colon carcinogenesis, indicating the plausibility of using these enzymes as intermediate biochemical markers of colon cancer.
Journal ArticleDOI
Effects of combination of calcium and aspirin on azoxymethane-induced aberrant crypt foci formation in the colons of mice and rats.
Yingying Liu,Jihyeung Ju,Hang Xiao,Barbara Simi,Xingpei Hao,Bandaru S. Reddy,Mou-Tuan Huang,Harold L. Newmark,Chung S. Yang +8 more
TL;DR: The results indicate that the combination of calcium and aspirin did not produce a synergistic effect on the ACF formation in AOM-treated mice and rats.
Journal ArticleDOI
Modulation of inducible nitric oxide synthase expression in rat intestinal cells by colon tumor promoters.
TL;DR: The data suggest a possible role of colon tumor promoters, DAG and DC, for iNOS over-expression through activation of the PKC pathway in an in vitro system using the rat intestinal cell line, RIE-1.
Journal ArticleDOI
Chemoprophylaxis of colon cancer
TL;DR: Experimental, epidemiologic, and clinical studies provide evidence that nonsteroidal antiinflammatory drugs, particularly the selective cyclooxygenase (COX)-2 inhibitors, including celecoxib and several phytochemicals, act as anticancer agents, however, several of these chemopreventive agents induce side effects at effective high dose levels.